Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016[J]. CA Cancer J Clin, 2016, 66(1): 7-30. https://www.researchgate.net/publication/290183302_Cancer_Statistics_2016

Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132. https://www.researchgate.net/publication/291830601_Cancer_Statistics_in_China_2015

Roudier MP, Morrissey C, True LD, et al. Histopathological assessment of prostate cancer bone osteoblastic metastases[J]. J Urol, 2008, 180(3): 1154-1160. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=fc2cdc3039afa998b192e70e40800dad

McAllister SS, Weinberg RA. The Tumour-Induced Systemic Environment as a Critical Regulator of Cancer Progression and Metastasis[J]. Nat Cell Biol, 2014, 16(8): 717-727. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM25082194

Haffner MC, Mosbruger T, Esopi DM, et al. Tracking the Clonal Origin of Lethal Prostate Cancer[J]. J Clin Invest, 2013, 123(11): 4918-4922. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM24135135

Robert PH, Gerald PM. Prostate Cancer: An Update[J]. CA Cancer J Clin, 1986, 36(5): 274-292. https://www.researchgate.net/publication/20063299_Prostate_Cancer_An_Update?ev=pub_cit

Perez-Lopez R, Lorente D, Blackledge MD, et al. Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer[J]. Radiology, 2016, 280(1): 151-160. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=a8049b990db0ecffa54a487fa47c5cb4

Cui BQ. Clinical application value of the whole body bone imaging for evaluating the characteristic of osseous metastasis in patients with prostate carcinoma[J]. Zhongguo Lin Chuang Yi Xue Ying Xiang Za Zhi, 2010, 21(11): 817-818. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zglcyxyxzz201011023

Min JW, Um SW, Yim JJ, et al. The role of whole-body FDG PET/CT, Tc^99m MDP bone scintigraphy, and serum alkaline phosphatase in detecting bone metastasis in patients with newly diagnosed lung cancer[J]. J Korean Med Sci, 2009, 24(2): 275-280. http://europepmc.org/articles/PMC2672128/

Bjurlin MA, Rosenkrantz AB, Beltran LS, et al. Imaging and evaluation of patients with high-risk prostate cancer[J]. Nat Rev Urol, 2015, 12(11): 617-628. https://www.nature.com/articles/nrurol.2015.242

Rybak LD, Rosenthal DI. Radiological imaging for the diagnosis of bone metastases[J]. Q J Nucl Med, 2001, 45(1): 53-64. https://www.researchgate.net/publication/11886250_Rybak_LD_Rosenthal_DIRadiological_imaging_for_the_diagnosis_of_bone_metastases_Q_J_Nucl_Med_45_53-64

Scutellari PN, Addonisio G, Righi R, et al. Diagnostic imaging of bone metastases[J]. Radiol Med, 2000, 100(6): 429-435. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM2973918

Zhou CY, Chen JZ, He JW, et al. Imaging analysis of bone metastases in the extremities[J]. Shi Yong Fang She Xue Za Zhi, 2013, 29(11): 1823-1825, 1843. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=syfsxzz201311027

Liao GX, Leng ZX, Xiao GY. Progress of imaging in the diagnosis of bone metastases of proatate cancer[J]. Guo Ji Fang She Yi Xue He Yi Xue Za Zhi, 2016, 40(6): 464-468. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=gwyx-fsyxhyxfc201606012

Pyka T, Okamoto S, Dahlbender M, et al. Comparison of bone scintigraphy and ⁶⁸Ga-PSMA PET for skeletal staging in prostate cancer[J]. Eur J Nucl Med Mol Imaging, 2016, 43(12): 2114-2121. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=e79f950ddd8018546b78d9db20cbdb1c

Song W, Li Y, Kang F, et al. Comparison of ⁶⁸Ga-PSMA-617 PET/CT and ⁹⁹Tcm-MDP bone scintigraphy for bone metastases in prostate cancer[J]. Zhonghua Mi Niao Wai Ke Za Zhi, 2018, 39(10): 766-770. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhmnwk201810011

Lenzo NP, Meyrick D, Turner JH. Review of Gallium-68 PSMA PET/CT imaging in the management of prostate cancer[J]. Diagnostics(Basel), 2018, 8(1): 16. https://www.researchgate.net/publication/323133501_Review_of_Gallium-68_PSMA_PETCT_Imaging_in_the_Management_of_Prostate_Cancer

Riola-Parada C, García-Cañamaque L, Pérez-Dueñas V, et al. Simultaneous PET/MRI vs. PET/CT in oncology. A systematic review[J]. Rev Esp Med Nucl Imagen Mol, 2016, 35(5): 306-312. https://www.researchgate.net/publication/305400572_Simultaneous_PETMRI_vs_PETCT_in_oncology_A_systematic_review?_sg=adJUvUX0Lyo00hF4EwNKCuB7p6CCFGDwEm8AAhMRFqMy0siWAgqs-3v3UUwzyqqg5A35x4WhZlrrqswQKDQQWg

Al-Salama ZT. Apalutamide: first global approval[J]. Drugs, 2018, 78(6): 699-705.

Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis-free survival in prostate cancer[J]. N Engl J Med, 2018, 378(15): 1408-1418. https://pubmed.ncbi.nlm.nih.gov/29420164/

Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy[J]. N Engl J Med, 2012, 367(13): 1187-1197. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM22894553

Fizazi K, Scher H, Molina A, et al. Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of the COU-AA-301 Randomised, Double-Blind, Placebo-Controlled Phase 3 Study[J]. Lancet Oncol, 2012, 13(10): 983-992. https://www.sciencedirect.com/science/article/abs/pii/S1470204512703790

Charles JR, Smith MR, Fizazi K, et al. Abiraterone Acetate Plus Prednisone Versus Placebo Plus Prednisone in Chemotherapy-Naive Men With Metastatic Castration-Resistant Prostate Cancer (COU-AA-302): Final Overall Survival Analysis of a Randomised, Double-Blind, Placebo-Controlled Phase 3 Study[J]. Lancet Oncol, 2015, 16(2): 152-160. https://www.sciencedirect.com/science/article/abs/pii/S1470204514712057

Joaquin M, Suzanne C, Shahneen S, et al. DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer[J]. N Engl J Med, 2015, 373(18): 1697-1708.

Errante D, Mannucci N, Bernardi D, et al. Comment on 'Jaw avascular bone necrosis associated with long-term use of biphosphonates' [J]. Ann Oncol, 2006, 17(2): 350-352. https://www.sciencedirect.com/science/article/pii/S0923753419403633

Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma[J]. J Natl Cancer Inst, 2002, 94(19): 1458-1468. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_PM12359855

Valcamoniaco F, Petrelli F, Ferrari L, et al. Is time to first skeletal-related event the best primary end point in the assessment of bisphosphonate efficacy in patients with castration-sensitive prostate cancer?[J]. J Clin Oncol, 2014, 32(32): 3684-3685. https://pubmed.ncbi.nlm.nih.gov/25225432/

Taneja SS. Re: Effect of Enzalutamide on Time to First Skeletal-Related Event, Pain, and Quality of Life in Men with Castration-Resistant Prostate Cancer: Results from the Randomised, Phase 3 AFFIRM Trial[J]. J Urol, 2015, 194(2): 392-393.

National Administration of Traditional Chinese Medicine Bureau, National Health Commission of the People's Republic of China. Standard for diagnosis and treatment of cancer pain(2018 edition)[J]. Quan Ke Yi Xue Lin Chuang Yu Jiao Yu, 2019, 17(1): 4-8. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=qkyxlcyjy201901003

Weinfurt KP, Anstrom KJ, Castel LD, et al. Effect of zoledronic acid on pain associated with bone metastasis in patients with prostate cancer[J]. Ann Oncol, 2006, 17(6): 986-989. https://www.sciencedirect.com/science/article/pii/S0923753419435679

Konski A, James J, Hartsell W, et al. Economic analysis of radiation therapy oncology group 97-14: multiple versus single fraction radiation treatment of patients with bone metastases[J]. Am J Clin Oncol, 2009, 32(4): 423-428. https://pubmed.ncbi.nlm.nih.gov/19546803/

Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short-versus long-course radiotherapy for palliation of painful bone metastases[J]. J Natl Cancer Inst, 2005, 97(11): 798-804.

Janjan N, Lutz ST, Bedwinek JM, et al. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology[J]. J Palliat Med, 2009, 12(5): 417-426. https://www.researchgate.net/publication/24402276_Therapeutic_Guidelines_for_the_Treatment_of_Bone_Metastasis_A_Report_from_the_American_College_of_Radiology_Appropriateness_Criteria_Expert_Panel_on_Radiation_Oncology

Chow E, Harris K, Fan G, et al. Palliative radiotherapy trials for bone metastases: a systematic review[J]. J Clin Oncol, 2007, 25(11): 1423-1436. https://pubmed.ncbi.nlm.nih.gov/17416863/

Jabbari S, Gerszten PC, Ruschin M, et al. Stereotactic body radiotherapy for spinal metastases: practice guidelines, outcomes, and risks[J]. Cancer J, 2016, 22(4): 280-289. https://www.researchgate.net/publication/305497962_Stereotactic_Body_Radiotherapy_for_Spinal_Metastases_Practice_Guidelines_Outcomes_and_Risks

Bickels J, Dadia S, Lidar Z. Surgical management of metastatic bone disease[J]. J Bone Joint Surg Am, 2009, 91(6): 1503-1516. https://pubmed.ncbi.nlm.nih.gov/19487532/

Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures[J]. Clin Orthop Relat Res, 1989, (249): 256-264. doi: 10.1007%2F978-1-4471-5451-8_123

Foster CC, Weichselbaum RR, Pitroda SP. Oligometastatic prostate cancer: Reality or figment of imagination?[J].Cancer, 2019, 125(3): 340-352. https://www.researchgate.net/publication/329457471_Oligometastatic_prostate_cancer_Reality_or_figment_of_imagination

Weichselbaum RR, Hellman S. Oligometastases revisited[J]. Nat Rev Clin Oncol, 2011, 8(6): 378-382. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=97e46f58c8a7c3bb5d7773f9878f9217

Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence:a prospective, randomized, multicenter phase Ⅱ trial[J]. J Clin Oncol, 2018, 36(5): 446-453.

Satkunasivam R, Kim AE, Desai M, et al. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis[J]. J Urol, 2015, 194(2): 378-385. https://xueshu.baidu.com/usercenter/paper/show?paperid=ac9160e5666925f6e1bd5aba9a019633&site=xueshu_se

Christian G, Jutta E, Christian GS, et al. Role of Radical Prostatectomy in Metastatic Prostate Cancer: Data From the Munich Cancer Registry[J]. Eur Urol, 2014, 66(3): 602-603. https://pubmed.ncbi.nlm.nih.gov/24821581/

Liu YJ, Yang RJ, Zhang XM, et al. Therapy of pelvis bone tumor by interventional therapy[J]. Jie Ru Fang She Xue Za Zhi, 2007, 4(16): 232-234. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=jrfsxzz200704006

He Y, Wu CG, Li MH, et al. Percutaneous vertebroplasty for metastatic lesions of the cervical spine[J]. Jie Ru Fang She Xue Za Zhi, 2012, 21(3): 225-230. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=jrfsxzz201203012

European Parthership Against Cancer consensus group, Albreht T, Audisio R, et al. Policy statement on multidisciplinary cancer care[J]. Eur J Cancer, 2014, 50(3): 475-480. https://www.sciencedirect.com/science/article/abs/pii/S0959804913010071

Hong NJL, Wright FC, Gagliardi AR, et al. Examining the potential relationship between multidisciplinary cancer care and patient survival: an international literature review[J]. J Surg Oncol, 2010, 102(2): 125-134. https://pubmed.ncbi.nlm.nih.gov/20648582/